Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CHUCNASDAQ:COYANASDAQ:CTNMNASDAQ:JSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHUCCharlie's$0.10-5.1%$0.10$0.03▼$0.19$25.79M0.9375,460 shs15,021 shsCOYACoya Therapeutics$6.27+8.4%$5.83$4.65▼$10.24$104.81M0.2672,443 shs72,677 shsCTNMContineum Therapeutics$3.98-0.6%$4.08$3.35▼$21.92$102.83M0.8590,707 shs143,855 shsJSPRJasper Therapeutics$7.04+3.2%$5.36$3.13▼$26.05$105.68M2.69315,538 shs336,840 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHUCCharlie's0.00%-0.30%-7.12%+65.33%-41.65%COYACoya Therapeutics0.00%+7.09%+6.55%+16.23%-3.62%CTNMContineum Therapeutics0.00%-3.28%-16.32%-25.98%-80.15%JSPRJasper Therapeutics0.00%+28.16%+17.07%+97.09%-66.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHUCCharlie's0.1929 of 5 stars0.03.00.00.00.01.70.0COYACoya Therapeutics2.3083 of 5 stars3.54.00.00.01.90.80.0CTNMContineum Therapeutics2.1669 of 5 stars3.61.00.00.00.00.81.3JSPRJasper Therapeutics2.0176 of 5 stars3.53.00.00.01.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHUCCharlie's 0.00N/AN/AN/ACOYACoya Therapeutics 3.00Buy$16.67166.03% UpsideCTNMContineum Therapeutics 3.17Buy$22.50466.04% UpsideJSPRJasper Therapeutics 3.00Buy$59.25742.10% UpsideCurrent Analyst Ratings BreakdownLatest CHUC, JSPR, CTNM, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/20/2025CTNMContineum TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform6/9/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/19/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.005/15/2025CTNMContineum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.005/15/2025JSPRJasper TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.005/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.004/28/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/22/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHUCCharlie's$8.49M3.04N/AN/A($0.01) per share-9.92COYACoya Therapeutics$3.55M29.52N/AN/A$2.37 per share2.64CTNMContineum Therapeutics$50M2.06N/AN/A$7.66 per share0.52JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHUCCharlie's-$4.16M-$0.01N/A∞N/A-55.89%N/A-104.63%8/18/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)CTNMContineum Therapeutics-$42.26M-$1.97N/AN/AN/AN/A-24.59%-23.49%8/12/2025 (Estimated)JSPRJasper Therapeutics-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)Latest CHUC, JSPR, CTNM, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2024CHUCCharlie'sN/A-$0.01N/A-$0.01N/A$1.78 million5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/12/2025Q1 2025JSPRJasper Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHUCCharlie'sN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHUCCharlie'sN/A0.510.06COYACoya TherapeuticsN/A8.848.84CTNMContineum TherapeuticsN/A21.4721.47JSPRJasper TherapeuticsN/A4.314.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHUCCharlie's7.80%COYACoya Therapeutics39.75%CTNMContineum TherapeuticsN/AJSPRJasper Therapeutics79.85%Insider OwnershipCompanyInsider OwnershipCHUCCharlie's20.90%COYACoya Therapeutics12.00%CTNMContineum Therapeutics11.30%JSPRJasper Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHUCCharlie's40259.95 million205.62 millionNot OptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableCTNMContineum Therapeutics3125.87 million22.95 millionN/AJSPRJasper Therapeutics2015.02 million14.33 millionOptionableCHUC, JSPR, CTNM, and COYA HeadlinesRecent News About These CompaniesJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $62.22 Consensus Price Target from AnalystsJune 28, 2025 | americanbankingnews.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from BrokeragesJune 25, 2025 | marketbeat.comJasper Therapeutics stock maintains buy rating on positive urticaria dataJune 18, 2025 | investing.comJasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible UrticariaJune 15, 2025 | nasdaq.comJasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinizedJune 15, 2025 | investing.comJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaJune 14, 2025 | globenewswire.comAnalysts Offer Predictions for JSPR FY2026 EarningsJune 10, 2025 | marketbeat.comJasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressJune 3, 2025 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash WiselyMay 29, 2025 | finance.yahoo.comJasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside PotentialMay 21, 2025 | insidermonkey.comJasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab DevelopmentMay 16, 2025 | nasdaq.comJasper Therapeutics to Present at Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comJasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 12, 2025 | globenewswire.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%May 6, 2025 | aaii.comAWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%April 22, 2025 | aaii.comAWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%April 11, 2025 | aaii.comAJasper Therapeutics inks new sales agreement, ends previous dealMarch 21, 2025 | uk.investing.comJasper Therapeutics files $300M mixed securities shelfMarch 19, 2025 | markets.businessinsider.comJasper Therapeutics presents updated data from Phase 1b/2a BEACON studyMarch 2, 2025 | msn.comJasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingMarch 1, 2025 | globenewswire.comJasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual MeetingFebruary 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHUC, JSPR, CTNM, and COYA Company DescriptionsCharlie's OTCMKTS:CHUC$0.10 -0.01 (-5.07%) As of 07/3/2025 12:22 PM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.Coya Therapeutics NASDAQ:COYA$6.26 +0.49 (+8.39%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$6.05 -0.22 (-3.50%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Contineum Therapeutics NASDAQ:CTNM$3.98 -0.03 (-0.63%) Closing price 07/3/2025 02:42 PM EasternExtended Trading$4.07 +0.10 (+2.42%) As of 07/3/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Jasper Therapeutics NASDAQ:JSPR$7.04 +0.22 (+3.17%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$6.90 -0.13 (-1.86%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.